

1 PATIENT INFORMATION Patient Name: _____ Phone: _____ Address: _____ City: _____ State: _____ Zip: _____ MRN #: _____ DOB: _____ Drug Allergies: _____	2 PRESCRIBER INFORMATION Prescriber's Name: _____ DEA#: _____ NPI: _____ Clinic/Facility Name: _____ Address: _____ City: _____ State: _____ ZIP: _____ Phone: _____ Fax: _____		
3 Instructions to Provider All orders with ✓ will be placed unless otherwise noted. Please fax completed order form to 206-326-2139. For drug prior authorization, call 1-888-767-4670 or visit https://wa-provider.kaiserpermanente.org/provider-manual/clinical-review/preservice			
4 CLINICAL INFORMATION Diagnosis (ICD-10 code): _____ Date of Last Dose: _____			
5 Efgartigimod alfa and hyaluronidase-qvfc (VYVGART[®] HYTRULO) PRESCRIPTION INFORMATION Efgartigimod alfa and hyaluronidase-qvfc (VYVGART [®] HYTRULO) 1008 mg and 11,200 units/5.6 mL Route: Subcutaneous Weight: _____ kg Date: _____ Dose: <input type="checkbox"/> 1,008 mg efgartigimod alfa/11,200 units hyaluronidase Frequency per treatment cycle: <input type="checkbox"/> once weekly for 4 weeks Treatment cycle: every _____ days from first dose of previous treatment cycle (no sooner than 50 days) Duration/Refills: _____ First Dose: <input type="checkbox"/> No <input type="checkbox"/> Yes Directions: Administer using a 25G, 12-inch tubing, PVC winged infusion set with a maximum priming volume of 0.4 mL. Before administration, attach syringe to winged infusion set; fill tubing of the infusion set by gently pressing syringe plunger until plunger is at 5.6 mL; there should be solution at the end of the infusion set needle. Choose an injection site on abdomen a minimum of 2 to 3 inches from the navel, avoiding areas with moles or scars, or where skin is red, bruised, or hard. Rotate injection sites for subsequent injections. Administer over a period of 30 to 90 seconds. Infusion Reaction Medications & Supplies <table style="width: 100%;"> <tr> <td style="width: 50%; vertical-align: top;"> <input checked="" type="checkbox"/> Hydrocortisone sodium succinate injectable 100 mg IV or IM Sig: Once PRN for hypersensitivity <input checked="" type="checkbox"/> Epinephrine Auto-Injector <input type="checkbox"/> 0.15mg <input type="checkbox"/> 0.3mg QTY: 2 Sig: Inject into lateral thigh muscle for severe allergic reaction. Seek medical attention after use. </td> <td style="width: 50%; vertical-align: top;"> <input checked="" type="checkbox"/> Diphenhydramine injectable 25 mg IV or IM Sig: Once PRN, may repeat x1 for urticaria, pruritis, shortness of breath <input checked="" type="checkbox"/> Sodium Chloride 0.9% IV 250 ml Bag IV Sig: Once PRN for anaphylaxis </td> </tr> </table> Labs /Special Instructions/Pre-Meds: _____ _____ _____		<input checked="" type="checkbox"/> Hydrocortisone sodium succinate injectable 100 mg IV or IM Sig: Once PRN for hypersensitivity <input checked="" type="checkbox"/> Epinephrine Auto-Injector <input type="checkbox"/> 0.15mg <input type="checkbox"/> 0.3mg QTY: 2 Sig: Inject into lateral thigh muscle for severe allergic reaction. Seek medical attention after use.	<input checked="" type="checkbox"/> Diphenhydramine injectable 25 mg IV or IM Sig: Once PRN, may repeat x1 for urticaria, pruritis, shortness of breath <input checked="" type="checkbox"/> Sodium Chloride 0.9% IV 250 ml Bag IV Sig: Once PRN for anaphylaxis
<input checked="" type="checkbox"/> Hydrocortisone sodium succinate injectable 100 mg IV or IM Sig: Once PRN for hypersensitivity <input checked="" type="checkbox"/> Epinephrine Auto-Injector <input type="checkbox"/> 0.15mg <input type="checkbox"/> 0.3mg QTY: 2 Sig: Inject into lateral thigh muscle for severe allergic reaction. Seek medical attention after use.	<input checked="" type="checkbox"/> Diphenhydramine injectable 25 mg IV or IM Sig: Once PRN, may repeat x1 for urticaria, pruritis, shortness of breath <input checked="" type="checkbox"/> Sodium Chloride 0.9% IV 250 ml Bag IV Sig: Once PRN for anaphylaxis		
Infusion Protocol: <ul style="list-style-type: none"> • Infuse per manufacturer guidelines • Monitor vital signs (Temp, BP, HR, RR) during infusion and for 60 minutes following completion of infusion. • Documentation must include: <ul style="list-style-type: none"> ○ Start and end time of infusion ○ Vital signs (including initial and final sets) ○ Patient response 	<ul style="list-style-type: none"> • Observe patient for signs of infusion rate-related adverse reactions: <ul style="list-style-type: none"> ○ Blood pressure changes, increased pulse rate ○ Fever, chills ○ Headache ○ Chest, back or hip pain ○ Dyspnea ○ Mild erythema 		
6 PHYSICIAN SIGNATURE REQUIRED			
X _____ SUBSTITUTION PERMITTED (Date)	X _____ DISPENSE AS WRITTEN (Date)		

CONFIDENTIALITY NOTICE: This message and any attached files might contain confidential information protected by federal and state law. The information is intended only for the use of the individual(s) or entities originally named as addressees. The improper disclosure of such information may be subject to civil or criminal penalties. If this message reached you in error, please contact the sender and destroy this message. Disclosing, copying, forwarding, or distributing the information by unauthorized individuals or entities is strictly prohibited by law.

Members with Medicare Part B or D coverage are not required to use this form.